New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14

Background: The issue of antimicrobial resistance (AMR) poses a major challenge to global health, evidenced by alarming mortality predictions and the diminishing efficiency of conventional antimicrobial drugs. The CRISPR-Cas system has proven to be a powerful tool in addressing this challenge. It or...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahmed S.A. Ali Agha, Ali Al-Samydai, Talal Aburjai
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844025003937
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832573050667663360
author Ahmed S.A. Ali Agha
Ali Al-Samydai
Talal Aburjai
author_facet Ahmed S.A. Ali Agha
Ali Al-Samydai
Talal Aburjai
author_sort Ahmed S.A. Ali Agha
collection DOAJ
description Background: The issue of antimicrobial resistance (AMR) poses a major challenge to global health, evidenced by alarming mortality predictions and the diminishing efficiency of conventional antimicrobial drugs. The CRISPR-Cas system has proven to be a powerful tool in addressing this challenge. It originated from bacterial adaptive immune mechanisms and has gained significant recognition in the scientific community. Objectives: This review aims to explore the applications of CRISPR-Cas technologies in combating AMR, evaluating their effectiveness, challenges, and potential for integration into current antimicrobial strategies. Methods: We conducted a comprehensive review of recent literature from databases such as PubMed and Web of Science, focusing on studies that employ CRISPR-Cas technologies against AMR. Conclusions: CRISPR-Cas technologies offer a transformative approach to combat AMR, with potential applications that extend beyond traditional antimicrobial strategies. Integrating these technologies with existing methods could significantly enhance our ability to manage and potentially reverse the growing problem of antimicrobial resistance. Future research should address technical and ethical barriers to facilitate safe and effective clinical and environmental applications. This review underscores the necessity for interdisciplinary collaboration and international cooperation to harness the full potential of CRISPR-Cas technologies in the fight against superbugs.
format Article
id doaj-art-01b6d554eb58438889a12d05abcffa7d
institution Kabale University
issn 2405-8440
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj-art-01b6d554eb58438889a12d05abcffa7d2025-02-02T05:28:47ZengElsevierHeliyon2405-84402025-01-01112e42013New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14Ahmed S.A. Ali Agha0Ali Al-Samydai1Talal Aburjai2School of Pharmacy, Department of Pharmaceutical Sciences, The University of Jordan, Amman, 11942, JordanPharmacological and Diagnostic Research Center, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Al-Ahliyya Amman University, (AA), Amman, 19328, JordanSchool of Pharmacy, Department of Pharmaceutical Sciences, The University of Jordan, Amman, 11942, Jordan; Corresponding author.Background: The issue of antimicrobial resistance (AMR) poses a major challenge to global health, evidenced by alarming mortality predictions and the diminishing efficiency of conventional antimicrobial drugs. The CRISPR-Cas system has proven to be a powerful tool in addressing this challenge. It originated from bacterial adaptive immune mechanisms and has gained significant recognition in the scientific community. Objectives: This review aims to explore the applications of CRISPR-Cas technologies in combating AMR, evaluating their effectiveness, challenges, and potential for integration into current antimicrobial strategies. Methods: We conducted a comprehensive review of recent literature from databases such as PubMed and Web of Science, focusing on studies that employ CRISPR-Cas technologies against AMR. Conclusions: CRISPR-Cas technologies offer a transformative approach to combat AMR, with potential applications that extend beyond traditional antimicrobial strategies. Integrating these technologies with existing methods could significantly enhance our ability to manage and potentially reverse the growing problem of antimicrobial resistance. Future research should address technical and ethical barriers to facilitate safe and effective clinical and environmental applications. This review underscores the necessity for interdisciplinary collaboration and international cooperation to harness the full potential of CRISPR-Cas technologies in the fight against superbugs.http://www.sciencedirect.com/science/article/pii/S2405844025003937CRISPR-CasSuperbugsAnti-microbial resistanceGene-editingAntimicrobial therapyCas12
spellingShingle Ahmed S.A. Ali Agha
Ali Al-Samydai
Talal Aburjai
New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14
Heliyon
CRISPR-Cas
Superbugs
Anti-microbial resistance
Gene-editing
Antimicrobial therapy
Cas12
title New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14
title_full New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14
title_fullStr New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14
title_full_unstemmed New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14
title_short New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14
title_sort new frontiers in crispr addressing antimicrobial resistance with cas9 cas12 cas13 and cas14
topic CRISPR-Cas
Superbugs
Anti-microbial resistance
Gene-editing
Antimicrobial therapy
Cas12
url http://www.sciencedirect.com/science/article/pii/S2405844025003937
work_keys_str_mv AT ahmedsaaliagha newfrontiersincrispraddressingantimicrobialresistancewithcas9cas12cas13andcas14
AT alialsamydai newfrontiersincrispraddressingantimicrobialresistancewithcas9cas12cas13andcas14
AT talalaburjai newfrontiersincrispraddressingantimicrobialresistancewithcas9cas12cas13andcas14